Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO Breast 2020 | The right biomarker for the right patient

Nicola Fusco • 13 May 2020

ESMO Breast 2020

Breast Cancer Antibodies Atezolizumab Nab-paclitaxel Pembrolizumab

IMpassion130

Nicola Fusco, MD, Istituto Europeo di Oncologia, Milan, Italy, outlines his talk at ESMO Breast 2020 titled ‘The right biomarker for the right patient: From immunohistochemistry to predictive molecular pathology of breast cancer (BC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Future directions of liquid biopsy for breast cancer

Future directions of liquid biopsy for breast cancer

Nicola Fusco • 25 Oct 2022

Liquid biopsy for breast cancer

Liquid biopsy for breast cancer

Nicola Fusco • 25 Oct 2022

PTEN protein and gene expression as a biomarker in breast cancer

PTEN protein and gene expression as a biomarker in breast cancer

Nicola Fusco • 13 May 2021

Mismatch repair protein loss in breast cancer

Mismatch repair protein loss in breast cancer

Nicola Fusco • 20 May 2020

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer

CRCI and compromised adjuvant chemotherapy delivery in cancer

Filippos Koinis • 1 Jun 2026

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC

Sarbajit Mukherjee • 1 Jun 2026

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC

Kevin Kalinsky • 31 May 2026

Clinical relevance of PFS2 in metastatic triple-negative breast cancer

Clinical relevance of PFS2 in metastatic triple-negative breast cancer

Kevin Kalinsky • 31 May 2026